BioNTech (NASDAQ:BNTX) Trading Up 2% – What’s Next?

BioNTech SE (NASDAQ:BNTX)’s stock price traded up 2% during trading on Monday . The stock traded as high as $115.98 and last traded at $115.39. 290,685 shares traded hands during trading, a decline of 64% from the average session volume of 810,922 shares. The stock had previously closed at $113.13.

Analysts Set New Price Targets

Several equities analysts recently issued reports on BNTX shares. HSBC upped their target price on BioNTech from $97.00 to $136.00 and gave the company a “buy” rating in a research report on Monday, October 7th. Berenberg Bank began coverage on BioNTech in a research note on Tuesday, November 19th. They issued a “buy” rating and a $130.00 price objective for the company. Canaccord Genuity Group reiterated a “buy” rating and issued a $171.00 target price on shares of BioNTech in a research report on Thursday, November 14th. Hsbc Global Res raised shares of BioNTech from a “hold” rating to a “strong-buy” rating in a research report on Friday, August 2nd. Finally, Deutsche Bank Aktiengesellschaft lifted their price objective on shares of BioNTech from $95.00 to $150.00 and gave the company a “buy” rating in a research note on Thursday, September 19th. Four analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $138.79.

BioNTech Stock Up 6.7 %

The firm’s 50 day simple moving average is $113.60 and its 200-day simple moving average is $97.80. The company has a market cap of $28.95 billion, a price-to-earnings ratio of -54.95 and a beta of 0.26. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings results on Monday, November 4th. The company reported $0.81 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.26) by $2.07. The firm had revenue of $1.24 billion for the quarter, compared to the consensus estimate of $514.08 million. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The firm’s quarterly revenue was up 38.9% compared to the same quarter last year. During the same quarter last year, the business posted $0.73 EPS. As a group, sell-side analysts anticipate that BioNTech SE will post -3.68 earnings per share for the current year.

Institutional Trading of BioNTech

A number of large investors have recently bought and sold shares of the business. Baillie Gifford & Co. raised its holdings in shares of BioNTech by 0.4% in the third quarter. Baillie Gifford & Co. now owns 8,308,071 shares of the company’s stock valued at $986,750,000 after buying an additional 31,773 shares during the last quarter. FMR LLC increased its holdings in shares of BioNTech by 797.8% in the third quarter. FMR LLC now owns 6,299,929 shares of the company’s stock valued at $748,243,000 after purchasing an additional 5,598,190 shares during the period. Deerfield Management Company L.P. Series C raised its stake in shares of BioNTech by 4.3% during the second quarter. Deerfield Management Company L.P. Series C now owns 594,000 shares of the company’s stock worth $47,734,000 after purchasing an additional 24,426 shares during the last quarter. Candriam S.C.A. lifted its holdings in shares of BioNTech by 261.2% during the second quarter. Candriam S.C.A. now owns 578,998 shares of the company’s stock worth $46,526,000 after purchasing an additional 418,695 shares during the period. Finally, Fred Alger Management LLC acquired a new stake in shares of BioNTech during the third quarter worth $59,485,000. Institutional investors and hedge funds own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.